Protocol Reference
Epitalon (AEDG)
Epitalon — research context, not a human protocol
Explain the state of the Epitalon literature and why no protocol summary is defensible.
Not FDA ApprovedReviewed September 1, 2026
No established human dosing protocol exists for this compound. What follows describes the research context only — the conditions under which the compound has been studied, usually in animals or in vitro.
Research Context
- Source of this information
- Epitalon protocols circulate widely in longevity communities. None of them can be traced to an adequately reported human trial.
- Evidence level
- Grade E — older regional studies and animal work with minimal independent replication
- Population studied
- Rodents in most studies; elderly cohorts in older Russian reports with limited methodological detail.
- Duration studied
- Reported courses of days to weeks, repeated periodically, in the original research tradition.
- Route reported
- Subcutaneous and intranasal administration reported.
Protocol as Reported
- 01No established human dosing protocol exists.
- 02Older Russian studies describe short courses of injections repeated at intervals, but reporting is insufficient to reconstruct a protocol with confidence.
- 03Cycling schedules shared in longevity communities are not derived from published trials.
Adverse Events Reported
- No modern safety dataset exists.
- Proposed telomerase activation raises unstudied oncological questions.
Limitations
- Evidence is concentrated in one research tradition with little independent replication.
- No controlled human outcome data support lifespan or healthspan claims.
Sources
- In-vitro study
Epithalon and telomerase activity in human somatic cells
Educational reference only. Peptide Atlas does not provide medical advice or individualised dosing guidance, and nothing on this page should be used to guide personal use.